Takeda reports additional data from Nesina CV outcomes trial

Share this article:

Takeda has released new data from its cardiovascular safety outcomes trial—EXAMINE—for DPP-4 inhibitor and diabetes treatment Nesina (alogliptin). The study investigated alogliptin's effect on rates of cardiovascular mortality and hospitalization for heart failure in patients with recent acute coronary syndrome.

The company said that its drug “demonstrated no effect on rates of CV mortality,” compared to placebo, and “there was also no increase in sudden cardiac death with alogliptin.”

The trial's principal investigator and abstract author, William B. White, MD, said in a statement, "Cardiovascular events are very common in patients with Type 2 diabetes, so it is important that diabetes treatments adequately manage glucose levels in these patients without adversely affecting cardiovascular outcomes, such as hospitalized heart failure and cardiac death. Based on data presented, alogliptin showed no difference from placebo on rates of cardiovascular mortality and hospitalized heart failure in this high-risk population of patients with Type 2 diabetes." 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters